Oncolytics Biotech, Inc. (ONCY)
0.871
-0.01
(-1.02%)
USD |
NASDAQ |
Sep 03, 10:42
Oncolytics Biotech Research and Development Expense (TTM) : 13.11M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 13.11M |
| March 31, 2026 | 10.77M |
| December 31, 2025 | 9.059M |
| September 30, 2025 | 13.10M |
| June 30, 2025 | 12.89M |
| March 31, 2025 | 14.24M |
| December 31, 2024 | 15.48M |
| September 30, 2024 | 15.65M |
| June 30, 2024 | 15.11M |
| March 31, 2024 | 14.60M |
| December 31, 2023 | 13.12M |
| September 30, 2023 | 13.27M |
| June 30, 2023 | 11.75M |
| March 31, 2023 | 11.51M |
| December 31, 2022 | 11.82M |
| September 30, 2022 | 11.17M |
| June 30, 2022 | 10.96M |
| March 31, 2022 | 11.06M |
| December 31, 2021 | 10.31M |
| September 30, 2021 | 10.51M |
| June 30, 2021 | 10.80M |
| March 31, 2021 | 9.992M |
| December 31, 2020 | 9.694M |
| September 30, 2020 | 8.620M |
| June 30, 2020 | 6.984M |
| Date | Value |
|---|---|
| March 31, 2020 | 7.729M |
| December 31, 2019 | 8.144M |
| September 30, 2019 | 8.380M |
| June 30, 2019 | 8.465M |
| March 31, 2019 | 7.624M |
| December 31, 2018 | 7.748M |
| September 30, 2018 | 7.332M |
| June 30, 2018 | 7.470M |
| March 31, 2018 | 7.989M |
| December 31, 2017 | 7.263M |
| September 30, 2017 | 8.001M |
| June 30, 2017 | 7.965M |
| March 31, 2017 | 7.079M |
| December 31, 2016 | 7.217M |
| September 30, 2016 | 6.309M |
| June 30, 2016 | 6.650M |
| March 31, 2016 | 7.206M |
| December 31, 2015 | 7.571M |
| September 30, 2015 | 8.083M |
| June 30, 2015 | 9.553M |
| March 31, 2015 | 10.94M |
| December 31, 2014 | 12.32M |
| September 30, 2014 | 14.53M |
| June 30, 2014 | 16.09M |
| March 31, 2014 | 16.87M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Sarepta Therapeutics, Inc. | 783.60M |
| Anixa Biosciences, Inc. | 4.557M |
| Vicapsys Life Sciences, Inc. | 0.0043M |